G6PD Deficiency and Malaria Implications

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common X-linked enzymopathy that reduces cellular capacity to produce NADPH, compromising redox balance in erythrocytes. In malaria-endemic regions, this inherited trait exerts a dual role: on one hand, it predisposes individuals to acute haemolysis when exposed to oxidant drugs such as primaquine; on the other hand, epidemiological evidence suggests a degree of protection against severe malaria, especially in heterozygous females. The global distribution of G6PD variants is highly heterogeneous, with distinct regional repertoires reflecting historical malaria selection pressures. Clinically, ensuring the safe use of 8-aminoquinoline therapies for radical cure of Plasmodium vivax and gametocytocidal treatment in falciparum malaria hinges on accurate assessment of G6PD activity. Limited access to reliable point-of-care diagnostics has led to underuse of primaquine despite its central role in elimination strategies. Advances in pharmacokinetic modelling, variant-specific molecular characterisation and geospatial mapping are informing policy and practice, aiming to balance the risks of drug-induced haemolysis against public health gains in malaria control and eradication.

Research from Nature Portfolio

Recent studies have elucidated the molecular impact of rare G6PD mutations on enzyme stability and function, revealing how specific amino acid substitutions disrupt dimerisation and thermal resilience. Detailed structural analyses of a novel Arg219Gly variant demonstrate a drastic reduction in catalytic activity and protein stability, offering a platform for the rational design of small-molecule activators to restore residual function. Complementing these mechanistic insights, a comprehensive meta-analysis of case–control studies assesses the association between G6PD deficiency and malaria outcomes across diverse endemic settings. The analysis confirms a modest protective effect against uncomplicated falciparum malaria in African heterozygotes, while no significant protection is observed against severe disease or in Asian populations, underscoring the complexity of host-pathogen interactions and the influence of variant severity.

G6PD Deficiency and Malaria Implications publication trend

The graph below shows the total number of articles in g6pd deficiency and malaria implications across all publications each year (not limited to Nature Index journals).

Technical terms

Glucose-6-phosphate dehydrogenase (G6PD): An enzyme in the pentose phosphate pathway that generates NADPH, critical for protecting red blood cells from oxidative damage.

Primaquine: An 8-aminoquinoline antimalarial used for radical cure of Plasmodium vivax and to eliminate gametocytes of P. falciparum.

Haemolysis: The destruction of red blood cells, which in G6PD deficiency can be triggered by oxidant drugs and certain foods.

Radical cure: The complete elimination of liver hypnozoites of P. vivax or P. ovale to prevent malaria relapse.

Heterozygous/hemizygous: Genetic terms describing individuals with one (heterozygous female) or a single (hemizygous male) copy of a mutant G6PD gene.

Geostatistical model: A spatial analysis technique that predicts disease or trait prevalence across regions based on survey data and statistical interpolation.

Meta-analysis: A quantitative synthesis of data from multiple studies to assess the overall effect size of an association or intervention.

References

1. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malaria Journal (2013).
2. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malaria Journal (2013).
3. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. PLOS Neglected Tropical Diseases (2018).
4. G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based Map. PLOS Medicine (2012).
5. Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers. eLife (2024).
6. Substitution of arginine 219 by glycine compromises stability, dimerization, and catalytic activity in a G6PD mutant. Communications Biology (2023).
7. Association of glucose-6-phosphate dehydrogenase deficiency and malaria: a systematic review and meta-analysis. Scientific Reports (2017).